Cervical progression.

Platinum-based chemo and bevacizumab are first-line systemic therapy for metastatic cervical cancer. Pembrolizumab is currently used in the second-line in this setting. KEYNOTE-826 was a randomized phase 3 trial that sought to determine if adding pembro to first-line chemo with (63%) or without bev at physician discretion would improve progression-free and overall survival. Whether looking at all comers or only patients with a combined positive score ≥ 1 (88%) or ≥ 10 (51%), median progression-free survival was improved from ~8 → ~10 months. At 24 months, the rate of overall survival was also significantly increased across all three groups from 40-45% → 50-55% with pembro. What’s more, the improvements with pembro were independent of PD-L1 status and treatment with bev. | Colombo, N Engl J Med 2021